1
|
Bell M, Lui H, Lee TK, Kalia S. Validation of medical service insurance claims as a surrogate for ascertaining vitiligo cases. Arch Dermatol Res 2023; 315:541-550. [PMID: 36173455 DOI: 10.1007/s00403-022-02383-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Revised: 04/23/2022] [Accepted: 08/02/2022] [Indexed: 11/02/2022]
Abstract
The epidemiology of vitiligo, especially its disease burden on the healthcare system, can be assessed indirectly by analyzing health insurance claims data. Validating this approach is integral to ensuring accurate case identification and cohort characterization. The primary aim of this study was to develop and validate an indirect measure of vitiligo ascertainment using health insurance claims data. These data were used secondarily to identify demographic characteristics, body site involvement, vitiligo subtypes, disease associations, and treatments. This study assessed the validity of identifying vitiligo from billing claims within a Canadian provincial universal health insurance program, versus vitiligo cases accrued from direct medical chart reviews. Claims-based algorithms combining ICD-9-CM diagnostic code 709 with treatment-specific data were derived and tested to identify vitiligo patients. This was compared against cases arising from the manual review of medical records of 606 patient with a diagnostic code for "dyschromia" (ICD-9-CM diagnostic code 709) from January 1 to December 31, 2016. Based on the chart reviews, 204 (33.7%) patients were confirmed to have vitiligo. 42 separate claims-based algorithms combining ICD-9-CM diagnostic code 709 with treatment data specific to vitiligo were modeled and individually tested to evaluate their accuracy for vitiligo ascertainment. One algorithm achieved a sensitivity, specificity, PPV and NPV of 86.8% (95% CI 82.1-91.4), 92.5% (95% CI 90.0-95.1), 85.5% (95% CI 80.7-90.3), and 93.2% (95% CI 90.8-95.7), respectively. There was a 2.2 female-to-male ratio. The most common medical treatments were tacrolimus (74.5%) and topical corticosteroids (54.3%). Hypertension (24.2%) and hypothyroidism (19.6%) were the predominant co-morbidities associated with vitiligo. Health insurance claims data can be used to indirectly ascertain vitiligo for epidemiologic purposes with relatively high diagnostic performance between 85.5 and 93.2%.
Collapse
Affiliation(s)
- M Bell
- Department of Dermatology and Skin Science, University of British Columbia, 835 West 10th Avenue, Vancouver, BC, V5Z 4E8, Canada
- Photomedicine Institute, Vancouver Coastal Health Research Institute, Vancouver, Canada
| | - H Lui
- Department of Dermatology and Skin Science, University of British Columbia, 835 West 10th Avenue, Vancouver, BC, V5Z 4E8, Canada
- Photomedicine Institute, Vancouver Coastal Health Research Institute, Vancouver, Canada
- Department of Cancer Control and/or Integrative Oncology and Imaging, BC Cancer, Vancouver, Canada
| | - T K Lee
- Department of Dermatology and Skin Science, University of British Columbia, 835 West 10th Avenue, Vancouver, BC, V5Z 4E8, Canada
- Photomedicine Institute, Vancouver Coastal Health Research Institute, Vancouver, Canada
- Department of Cancer Control and/or Integrative Oncology and Imaging, BC Cancer, Vancouver, Canada
| | - S Kalia
- Department of Dermatology and Skin Science, University of British Columbia, 835 West 10th Avenue, Vancouver, BC, V5Z 4E8, Canada.
- Photomedicine Institute, Vancouver Coastal Health Research Institute, Vancouver, Canada.
- Department of Cancer Control and/or Integrative Oncology and Imaging, BC Cancer, Vancouver, Canada.
- Centre for Clinical Evaluation and Epidemiology, Vancouver Coastal Health Research Institute, Vancouver, Canada.
- Division of Dermatology, BC Children's Hospital Research Institute, Vancouver, Canada.
| |
Collapse
|